转移性儿童甲状腺癌的遗传学特征和预后

doi:10.19401/j.cnki.1007-3639.2022.05.001

中国癌症杂志 ›› 2022, Vol. 32 ›› Issue (5): 373-379.doi: 10.19401/j.cnki.1007-3639.2022.05.001

转移性儿童甲状腺癌的遗传学特征和预后

曲以平¹()(), 侯鹏²^,³()()

1.西安交通大学第一附属医院肿瘤放疗科,陕西西安 710061
2.西安交通大学第一附属医院内分泌代谢科,陕西西安 710061
3.陕西省肿瘤精准医学重点实验室,陕西西安 710061

收稿日期:2022-03-14 修回日期:2022-04-29 出版日期:2022-05-30 发布日期:2022-06-09
通信作者: 侯鹏 E-mail:15398036489@163.com;phou@xjtu.edu.cn
作者简介:曲以平（ORCID: 0000-0002-3674-9158）,博士,助理研究员 E-mail: 15398036489@163.com
侯鹏,教授,博士研究生导师,西安交通大学第一附属医院内分泌代谢科副主任,西安交通大学第九批“腾飞”特聘教授及第一批“青年拔尖人才”,陕西省中青年科技创新领军人才,陕西省肿瘤精准医学重点实验室副主任。2005—2009年在美国约翰·霍普金斯大学医学院从事博士后研究工作,主要研究方向为内分泌系统肿瘤。2009年9月受聘于西安交通大学第一附属医院,并获得光华基金资助（光华特聘教授）,2010年入选教育部新世纪优秀人才支持计划。近年来,主持国家自然科学基金6项、973计划子课题1项、省部级项目4项,以第一作者或通信作者在SCI收录期刊上发表论文95篇（其中在影响因子>10的期刊上发表19篇,H指数为40）,获得陕西省科学技术奖二等奖及中华医学科技奖三等奖各1项。

Genetic characteristics and prognosis of metastatic thyroid cancer in children

QU Yiping¹()(), HOU Peng²^,³()()

1. Department of Radiation Oncology, The First Affiliated Hospital of Xi’an Jiao Tong University, Xi’an 710061, Shannxi Province, China
2. Department of Endocrinology, The First Affiliated Hospital of Xi’an Jiao Tong University, Xi’an 710061, Shannxi Province, China
3. Key Laboratory for Tumor Precision Medicine of Shaanxi Province, Xi’an 710061, Shannxi Province, China

Received:2022-03-14 Revised:2022-04-29 Published:2022-05-30 Online:2022-06-09
Contact: HOU Peng E-mail:15398036489@163.com;phou@xjtu.edu.cn

摘要/Abstract

摘要：

甲状腺癌的发病率随着年龄的增长而增加,虽然儿童甲状腺癌的发病率远低于成人,但在世界范围内甲状腺癌已经成为0~14岁儿童第5大常见癌症以及青少年最常见的癌症。不同于成人患者,目前普遍认为儿童甲状腺癌发病率的增加更有可能是基因或环境因素所致,并且儿童甲状腺癌在发病时往往更趋近于晚期,其复发率也远高于成人甲状腺癌,但是儿童甲状腺癌的分子病理学特征与肿瘤转移的关系仍有待进一步明确。本文将结合国内外研究进行综述,重点讨论转移性儿童甲状腺癌的遗传学特征,为研究者和临床医师针对儿童甲状腺癌的基础研究和肿瘤防治提供参考。

关键词: 儿童甲状腺癌, 肿瘤转移, 分子病理, 预后

Abstract:

The incidence rate of thyroid cancer increases with age. Although the incidence rate of thyroid cancer in children is far lower than in adults, thyroid cancer has become the fifth most common cancer among children aged 0-14 and the most common cancer among adolescents worldwide. Unlike thyroid cancer in adults, the increase in the incidence of thyroid cancer in children is more likely to be caused by genetic or environmental factors. Moreover, thyroid cancer in children tends to be late stage, and the recurrence rate is much higher than in adults. However, the relationship between molecular pathological characteristics and metastasis of thyroid cancer in children still needs to be further clarified. This review focused on the genetic changes of metastatic thyroid cancer in children in order to provide the reference for researchers and clinicians to better understand basic research, prevention and treatment of thyroid cancer in children.

Key words: Childhood thyroid carcinoma, Metastasis, Molecular pathology, Prognosis

中图分类号:

R736.1

曲以平, 侯鹏. 转移性儿童甲状腺癌的遗传学特征和预后[J]. 中国癌症杂志, 2022, 32(5): 373-379.

QU Yiping, HOU Peng. Genetic characteristics and prognosis of metastatic thyroid cancer in children[J]. China Oncology, 2022, 32(5): 373-379.

参考文献 63

[1]	PAULSON V A, RUDZINSKI E R, HAWKINS D S. Thyroid cancer in the pediatric population[J]. Genes, 2019, 10(9): 723. doi: 10.3390/genes10090723
[2]	HANLEY P, LORD K, BAUER A J. Thyroid disorders in children and adolescents: a review[J]. JAMA Pediatr, 2016, 170(10): 1008-1019. doi: 10.1001/jamapediatrics.2016.0486
[3]	BAUER A J. Pediatric thyroid cancer: genetics, therapeutics and outcome[J]. Endocrinol Metab Clin North Am, 2020, 49(4): 589-611. doi: 10.1016/j.ecl.2020.08.001
[4]	LUZÓN-TORO B, FERNÁNDEZ R, VILLALBA-BENITO L, et al. Influencers on thyroid cancer onset: molecular genetic basis[J]. Genes, 2019, 10(11): 913. doi: 10.3390/genes10110913
[5]	CHAN C M, YOUNG J, PRAGER J, et al. Pediatric thyroid cancer[J]. Adv Pediatr, 2017, 64(1): 171-190. doi: 10.1016/j.yapd.2017.03.007
[6]	PARISI M T, KHALATBARI H, PARIKH S R, et al. Initial treatment of pediatric differentiated thyroid cancer: a review of the current risk-adaptive approach[J]. Pediatr Radiol, 2019, 49(11): 1391-1403. doi: 10.1007/s00247-019-04457-7
[7]	CHESOVER A D, VALI R, HEMMATI S H, et al. Lung metastasis in children with differentiated thyroid cancer: factors associated with diagnosis and outcomes of therapy[J]. Thyroid, 2021, 31(1): 50-60. doi: 10.1089/thy.2020.0002
[8]	KIRATLI P O, VOLKAN-SALANCI B, GÜNAY E C, et al. Thyroid cancer in pediatric age group: an institutional experience and review of the literature[J]. J Pediatr Hematol Oncol, 2013, 35(2): 93-97. doi: 10.1097/MPH.0b013e3182755d9e
[9]	DERMODY S, WALLS A, HARLEY E H Jr. Pediatric thyroid cancer: an update from the SEER database 2007-2012[J]. Int J Pediatr Otorhinolaryngol, 2016, 89: 121-126. doi: 10.1016/j.ijporl.2016.08.005
[10]	CHRISTISON-LAGAY E, BAERTSCHIGER R M. Management of differentiated thyroid carcinoma in pediatric patients[J]. Surg Oncol Clin N Am, 2021, 30(2): 235-251. doi: 10.1016/j.soc.2020.11.013
[11]	LEE Y A, JUNG H W, KIM H Y, et al. Pediatric patients with multifocal papillary thyroid cancer have higher recurrence rates than adult patients: a retrospective analysis of a large pediatric thyroid cancer cohort over 33 years[J]. J Clin Endocrinol Metab, 2015, 100(4): 1619-1629. doi: 10.1210/jc.2014-3647
[12]	CORDIOLI M I, MORAES L, CURY A N, et al. Are we really at the dawn of understanding sporadic pediatric thyroid carcinoma?[J]. Endocr Relat Cancer, 2015, 22(6): R311-R324. doi: 10.1530/ERC-15-0381
[13]	O’GORMAN C S, HAMILTON J, RACHMIEL M, et al. Thyroid cancer in childhood: a retrospective review of childhood course[J]. Thyroid, 2010, 20(4): 375-380. doi: 10.1089/thy.2009.0386
[14]	NIKIFOROV Y E. Radiation-induced thyroid cancer: what we have learned from Chernobyl[J]. Endocr Pathol, 2006, 17(4): 307-317. doi: 10.1007/s12022-006-0001-5
[15]	FEINMESSER R, LUBIN E, SEGAL K, et al. Carcinoma of the thyroid in children: a review[J]. J Pediatr Endocrinol Metab, 1997, 10(6): 561-568.
[16]	AL-QURAYSHI Z, HAUCH A, SRIVASTAV S, et al. A national perspective of the risk, presentation, and outcomes of pediatric thyroid cancer[J]. JAMA Otolaryngol Head Neck Surg, 2016, 142(5): 472-478. doi: 10.1001/jamaoto.2016.0104
[17]	RUSSO M, MALANDRINO P, MOLETI M, et al. Differentiated thyroid cancer in children: heterogeneity of predictive risk factors[J]. Pediatr Blood Cancer, 2018, 65(9): e27226. doi: 10.1002/pbc.27226
[18]	NGO D Q, LE D T, NGO Q X, et al. Risk factors for lateral lymph node metastasis of papillary thyroid carcinoma in children[J]. J Pediatr Surg, 2022
[19]	BAUMGARTEN H, JENKS C M, ISAZA A, et al. Bilateral papillary thyroid cancer in children: risk factors and frequency of postoperative diagnosis[J]. J Pediatr Surg, 2020, 55(6): 1117-1122. doi: 10.1016/j.jpedsurg.2020.02.040
[20]	NGO D Q, NGO Q X, VAN LE Q. Pediatric thyroid cancer: risk factors for central lymph node metastasis in patients with cN₀ papillary carcinoma[J]. Int J Pediatr Otorhinolaryngol, 2020, 133: 110000. doi: 10.1016/j.ijporl.2020.110000
[21]	RUBINSTEIN J C, HERRICK-REYNOLDS K, DINAUER C, et al. Recurrence and complications in pediatric and adolescent papillary thyroid cancer in a high-volume practice[J]. J Surg Res, 2020, 249: 58-66. doi: 10.1016/j.jss.2019.12.002
[22]	KIM J, SUN Z F, ADAM M A, et al. Predictors of nodal metastasis in pediatric differentiated thyroid cancer[J]. J Pediatr Surg, 2017, 52(1): 120-123. doi: 10.1016/j.jpedsurg.2016.10.033
[23]	LIU Z M, HU D, HUANG Y H, et al. Factors associated with distant metastasis in pediatric thyroid cancer: evaluation of the SEER database[J]. Endocr Connect, 2019, 8(2): 78-85. doi: 10.1530/EC-18-0441
[24]	SHUKLA N, OSAZUWA-PETERS N, MEGWALU U C. Association between age and nodal metastasis in papillary thyroid carcinoma[J]. Otolaryngol Head Neck Surg, 2021, 165(1): 43-49. doi: 10.1177/0194599820966995
[25]	TANG A L, KLOOS R T, AUNINS B, et al. Pathologic features associated with molecular subtypes of well-differentiated thyroid cancer[J]. Endocr Pract, 2021, 27(3): 206-211. doi: 10.1016/j.eprac.2020.09.003
[26]	GALUPPINI F, VIANELLO F, CENSI S, et al. Differentiated thyroid carcinoma in pediatric age: genetic and clinical scenario[J]. Front Endocrinol (Lausanne), 2019, 10: 552. doi: 10.3389/fendo.2019.00552
[27]	IWADATE M, MITSUTAKE N, MATSUSE M, et al. The clinicopathological results of thyroid cancer with BRAF V600E mutation in the young population of fukushima[J]. J Clin Endocrinol Metab, 2020, 105(12): dgaa573.
[28]	DECAUSSIN-PETRUCCI M, DELADOËY J, HAFDI-NEJJARI Z, et al. Expression of CD133 in differentiated thyroid cancer of young patients[J]. J Clin Pathol, 2015, 68(6): 434-440. doi: 10.1136/jclinpath-2014-202625
[29]	CORDIOLI M I C V, MORAES L, CARVALHEIRA G, et al. AGK-BRAF gene fusion is a recurrent event in sporadic pediatric thyroid carcinoma[J]. Cancer Med, 2016, 5(7): 1535-1541. doi: 10.1002/cam4.698
[30]	ALZAHRANI A S, ALSWAILEM M, ALSWAILEM A A, et al. Genetic alterations in pediatric thyroid cancer using a comprehensive childhood cancer gene panel[J]. J Clin Endocrinol Metab, 2020, 105(10): dgaa389.
[31]	ELISEI R, ROMEI C, VORONTSOVA T, et al. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults[J]. J Clin Endocrinol Metab, 2001, 86(7): 3211-3216.
[32]	ZEINDL-EBERHART E, LIEBMANN S, JUNGBLUT P R, et al. Influence of RET/PTC1 and RET/PTC3 oncoproteins in radiation-induced papillary thyroid carcinomas on amounts of cytoskeletal protein species[J]. Amino Acids, 2011, 41(2): 415-425. doi: 10.1007/s00726-010-0733-x
[33]	MOSTOUFI-MOAB S, LABOURIER E, SULLIVAN L, et al. Molecular testing for oncogenic gene alterations in pediatric thyroid lesions[J]. Thyroid, 2018, 28(1): 60-67. doi: 10.1089/thy.2017.0059
[34]	FRANCO A T, RICARTE-FILHO J C, ISAZA A, et al. Fusion oncogenes are associated with increased metastatic capacity and persistent disease in pediatric thyroid cancers[J]. J Clin Oncol, 2022, 40(10): 1081-1090.
[35]	SASSOLAS G, HAFDI-NEJJARI Z, FERRARO A, et al. Oncogenic alterations in papillary thyroid cancers of young patients[J]. Thyroid, 2012, 22(1): 17-26. doi: 10.1089/thy.2011.0215
[36]	OISHI N, KONDO T, NAKAZAWA T, et al. Frequent BRAF V600E and absence of TERT promoter mutations characterize sporadic pediatric papillary thyroid carcinomas in Japan[J]. Endocr Pathol, 2017, 28(2): 103-111. doi: 10.1007/s12022-017-9470-y
[37]	ONDER S, OZTURK SARI S, YEGEN G, et al. Classic architecture with multicentricity and local recurrence, and absence of TERT promoter mutations are correlates of BRAF (V600E) harboring pediatric papillary thyroid carcinomas[J]. Endocr Pathol, 2016, 27(2): 153-161. doi: 10.1007/s12022-016-9420-0
[38]	OTSUBO R, MUSSAZHANOVA Z, AKAZAWA Y, et al. Sporadic pediatric papillary thyroid carcinoma harboring the ETV6/NTRK3 fusion oncogene in a 7-year-old Japanese girl: a case report and review of literature[J]. J Pediatr Endocrinol Metab, 2018, 31(4): 461-467. doi: 10.1515/jpem-2017-0292
[39]	SCOUTEN W T, PATEL A, TERRELL R, et al. Cytoplasmic localization of the paired box gene, Pax-8, is found in pediatric thyroid cancer and may be associated with a greater risk of recurrence[J]. Thyroid, 2004, 14(12): 1037-1046. doi: 10.1089/thy.2004.14.1037
[40]	STOSIC A, FULIGNI F, ANDERSON N D, et al. Diverse oncogenic fusions and distinct gene expression patterns define the genomic landscape of pediatric papillary thyroid carcinoma[J]. Cancer Res, 2021, 81(22): 5625-5637. doi: 10.1158/0008-5472.CAN-21-0761
[41]	FRANCO A T, LABOURIER E, ABLORDEPPEY K K, et al. miRNA expression can classify pediatric thyroid lesions and increases the diagnostic yield of mutation testing[J]. Pediatr Blood Cancer, 2020, 67(6): e28276.
[42]	ELOY C, SANTOS J, SOARES P, et al. Intratumoural lymph vessel density is related to presence of lymph node metastases and separates encapsulated from infiltrative papillary thyroid carcinoma[J]. Virchows Arch, 2011, 459(6): 595-605. doi: 10.1007/s00428-011-1161-3
[43]	SHIMURA K, SHIBATA H, MIZUNO Y, et al. Rapid growth and early metastasis of papillary thyroid carcinoma in an adolescent girl with Graves' disease[J]. Horm Res Paediatr, 2019, 91(3): 210-215. doi: 10.1159/000491102
[44]	CORDIOLI M I C V, MORAES L, ALVES M T, et al. Thyroid-specific genes expression uncovered age-related differences in pediatric thyroid carcinomas[J]. Int J Endocrinol, 2016, 2016: 1956740.
[45]	JARZAB B, HANDKIEWICZ-JUNAK D. Differentiated thyroid cancer in children and adults: same or distinct disease?[J]. Hormones (Athens), 2007, 6(3): 200-209.
[46]	LAN X B, BAO H, GE X Y, et al. Genomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasis[J]. Cancer Sci, 2020, 111(6): 2163-2173. doi: 10.1111/cas.14389
[47]	ZANELLA A B, SCHEFFEL R S, NAVA C F, et al. Dynamic risk stratification in the follow-up of children and adolescents with differentiated thyroid cancer[J]. Thyroid, 2018, 28(10): 1285-1292. doi: 10.1089/thy.2018.0075
[48]	NIKIFOROV Y E. Thyroid carcinoma: molecular pathways and therapeutic targets[J]. Mod Pathol, 2008, 21(Suppl 2): S37-S43. doi: 10.1038/modpathol.2008.10
[49]	DINAUER C A, BREUER C, RIVKEES S A. Differentiated thyroid cancer in children: diagnosis and management[J]. Curr Opin Oncol, 2008, 20(1): 59-65. doi: 10.1097/CCO.0b013e3282f30220
[50]	FRANCIS G L, WAGUESPACK S G, BAUER A J, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2015, 25(7): 716-759. doi: 10.1089/thy.2014.0460
[51]	SUBBIAH V, HU M I, WIRTH L J, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study[J]. Lancet Diabetes Endocrinol, 2021, 9(8): 491-501. doi: 10.1016/S2213-8587(21)00120-0
[52]	BRADFORD D, LARKINS E, MUSHTI S L, et al. FDA approval summary: selpercatinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions[J]. Clin Cancer Res, 2021, 27(8): 2130-2135. doi: 10.1158/1078-0432.CCR-20-3558
[53]	BROSE M S, NUTTING C M, JARZAB B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial[J]. Lancet, 2014, 384(9940): 319-328. doi: 10.1016/S0140-6736(14)60421-9
[54]	FENG G L, LUO Y, ZHANG Q, et al. Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis[J]. Endocrine, 2020, 68(1): 56-63. doi: 10.1007/s12020-019-02167-6
[55]	HIGUCHI Y, MOTOKI T, ISHIDA H, et al. Sorafenib treatment for papillary thyroid carcinoma with diffuse lung metastases in a child with autism spectrum disorder: a case report[J]. BMC Cancer, 2017, 17(1): 775. doi: 10.1186/s12885-017-3782-7
[56]	WELLS S A Jr, ROBINSON B G, GAGEL R F, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase Ⅲ trial[J]. J Clin Oncol, 2012, 30(2): 134-141.
[57]	GRANDE E, KREISSL M C, FILETTI S, et al. Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies[J]. Adv Ther, 2013, 30(11): 945-966. doi: 10.1007/s12325-013-0069-5
[58]	FOX E, WIDEMANN B C, CHUK M K, et al. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma[J]. Clin Cancer Res, 2013, 19(15): 4239-4248. doi: 10.1158/1078-0432.CCR-13-0071
[59]	FERRARI S M, ELIA G, RAGUSA F, et al. Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer[J]. Expert Opin Investig Drugs, 2021, 30(9): 913-921. doi: 10.1080/13543784.2021.1972971
[60]	MATRONE A, PRETE A, NERVO A, et al. Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer[J]. J Endocrinol Invest, 2021, 44(10): 2139-2151. doi: 10.1007/s40618-020-01491-3
[61]	MAHAJAN P, DAWRANT J, KHERADPOUR A, et al. Response to lenvatinib in children with papillary thyroid carcinoma[J]. Thyroid, 2018, 28(11): 1450-1454. doi: 10.1089/thy.2018.0064
[62]	GASPAR N, CAMPBELL-HEWSON Q, MELCON S G, et al. Phase Ⅰ/Ⅱ study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)[J]. ESMO Open, 2021, 6(5): 100250. doi: 10.1016/j.esmoop.2021.100250
[63]	ZHANG Y C, DENG X Z, DING Z, et al. Preoperative neoadjuvant targeted therapy with apatinib for inoperable differentiated thyroid cancer: a case report[J]. Medicine, 2021, 100(12): e25191. doi: 10.1097/MD.0000000000025191

转移性儿童甲状腺癌的遗传学特征和预后

Genetic characteristics and prognosis of metastatic thyroid cancer in children

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 63

相关文章 15

编辑推荐

Metrics

本文评价

[1]	高鹤丽, 徐近, 虞先濬. 2021年胰腺神经内分泌肿瘤诊治的新进展[J]. 中国癌症杂志, 2022, 32(9): 772-778.
[2]	张日虹, 郭宇, 梁贇, 陈洛海, 陈洁, 王玮. 辅助化疗对胃神经内分泌癌患者预后的意义[J]. 中国癌症杂志, 2022, 32(9): 807-817.
[3]	曹孟轩, 胡灿, 张延强, 黄灵, 杜义安, 于鹏程, 章若岚, 徐志远, 程向东. 胃癌根治术后早期复发转移的危险因素分析[J]. 中国癌症杂志, 2022, 32(7): 588-595.
[4]	钱瑶(综述), 刘锋(审校). 乳腺癌新辅助内分泌治疗的研究进展及展望[J]. 中国癌症杂志, 2022, 32(7): 643-649.
[5]	刘彦权, 胡晓梅, 殷悦, 林霖, 沈建箴, 陈玉婷, 唐焕文. 器官移植术后淋巴组织增生性疾病的临床回顾性研究[J]. 中国癌症杂志, 2022, 32(7): 650-656.
[6]	马光, 区晓敏, 胡超苏, 宋少莉, 杨忠毅. 治疗前¹⁸F-FLT和¹⁸F-FDG PET/CT摄取异质性在局部晚期鼻咽癌疗效预测中的价值[J]. 中国癌症杂志, 2022, 32(4): 309-315.
[7]	周长帅, 杨越超, 崔欢欢, 陈磊, 陈鑫, 郝斌, 童彤, 曹依群. 36例小脑转移瘤外科治疗及预后因素分析[J]. 中国癌症杂志, 2022, 32(4): 357-362.
[8]	杨贻兰, 赵旭, 陈星星, 汪宣伊, 金恺睿, 章真, 邵志敏, 郭小毛, 俞晓立. 乳腺导管原位癌的单中心预后分析[J]. 中国癌症杂志, 2022, 32(3): 228-233.
[9]	王子茂, 曹原, 王琪影. 皮肤梭形细胞黑色素瘤患者生存预测模型的构建及验证[J]. 中国癌症杂志, 2022, 32(3): 234-242.
[10]	陈玺, 曾晓颖, 陈佳艳, 刘菲, 唐曦. 错配修复蛋白联合血清肿瘤标志物与Ki-67增殖指数对结直肠癌预后的临床价值[J]. 中国癌症杂志, 2022, 32(3): 243-250.
[11]	侯清华, 钟燕凤, 刘林壮, 吴柳盛, 刘继先. CBX3在肺腺癌中的表达、预后相关性及对癌细胞生物学行为的影响[J]. 中国癌症杂志, 2022, 32(2): 152-160.
[12]	林艺, 王策, 康勋, 康庄, 陈峰, 江波, 李文斌. 胶质母细胞瘤复发相关基因的筛选、表达和临床预后分析[J]. 中国癌症杂志, 2022, 32(1): 13-23.
[13]	马祎菲, 梁新军, 魏少忠 . 炎症与免疫指标在可切除性结直肠癌中的预后价值[J]. 中国癌症杂志, 2021, 31(9): 845-851.
[14]	雷雅洁, 高　毅, 王治洁, 程　玺, 杨雨菲, 周宏宇, 陈丽华, 陈伊新, 李浩然, 李子庭, 吴小华 . 早期卵巢癌（Ⅰ C ~ⅡA）患者腹主动脉旁淋巴结清扫术对预后影响的临床分析[J]. 中国癌症杂志, 2021, 31(8): 740-745.
[15]	高鹤丽, 徐　近, 虞先濬. 分化好的胃肠胰神经内分泌瘤G3的诊治新进展[J]. 中国癌症杂志, 2021, 31(7): 567-573.